[1] Smith, C. J., Ali, A., Hammond, M. L., Li, H., Lu, Z., Napolitano, J., Taylor, G. E., Thompson, C. F., Anderson, M. S., Chen, Y., Eveland, S. S., Guo, Q., Hyland, S. A., Milot, D. P., Sparrow, C. P., Wright, S. D., Cumiskey, A.-M., Latham, M., Peterson, L. B., … Sinclair, P. J. (2011). Biphenyl-Substituted Oxazolidinones as Cholesteryl Ester Transfer Protein Inhibitors: Modifications of the Oxazolidinone Ring Leading to the Discovery of Anacetrapib. Journal of Medicinal Chemistry, 54(13), 4880–4895.
https://doi.org/10.1021/jm200484c [2] Bradbury, J. D., Hodgkinson, T., Thomas, A. M., Tanwar, O., Monica, G. L., Rogga, V. V., Mackay, L. J., Taylor, E. K., Gilbert, K., Zhu, Y., Sefton, A. Y., Edwards, A. M., Gray-Hammerton, C. J., Smith, G. R., Roberts, P. M., Walsh, T. R., & Lanyon-Hogg, T. (2024). Development of an inhibitor of the mutagenic SOS response that suppresses the evolution of quinolone antibiotic resistance. Chemical Science, 15(25), 9620–9629.
https://doi.org/10.1039/d4sc00995a